Updosing - Open Access .click

Results 41 to 50 of about 578 (168)

Efficacy and Safety of Abatacept Versus Placebo During Peanut Oral Immunotherapy for Adults With Severe Peanut Allergy

Allergy, EarlyView.
In this Phase 2a trial, severely peanut‐allergic participants were randomized to abatacept versus placebo with peanut oral immunotherapy (OIT) for 24 weeks, followed by 12 weeks of OIT alone. No significant difference was observed for the primary efficacy outcome (the relative change from baseline in peanut‐specific/total IgE ratio at 24 weeks), but ...
Marie‐Lee Simard +12 more
wiley +1 more source

Sublingual immunotherapy: administration, dosages, use [PDF]

, 2009
Allergen extracts for sublingual immunotherapy (SLIT) are currently marketed by several manufacturers, with administration schedules and amount of allergen(s) quite variable in the different products, although almost all are standardized biologically or ...
Incorvaia, C. +7 more
core +1 more source

Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract

, 2016
BACKGROUND: Allergen immunotherapy is an effective treatment of allergic rhinoconjunctivitis. Clinical efficacy is associated with improvement of basophil sensitivity and an increase in allergen-specific immunoglobulin concentration.OBJECTIVE: We sought ...
Peter Adler Würtzen +7 more
core +1 more source

Pathophysiology and emerging treatments for dermographic, cholinergic and cold urticaria

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This review illustrates key proposed mast cell‐mediated activation pathways in dermographic, cholinergic and cold urticaria, highlighting IgE‐dependent and ‐independent mechanisms. These pathways are increasingly targeted by emerging drugs, aiming to interrupt mast cell activation and mediator release, offering more precise, mechanism‐based treatment ...
Mojca Bizjak‐Suran, Matjaž Fležar, Manuel Pedro Pereira +2 more
wiley +1 more source

Safety of Peanut (Arachis Hypogaea) Allergen Powder-dnfp in Children and Teenagers With Peanut Allergy: Pooled Analysis From Controlled and Open-Label Phase 3 Trials [PDF]

, 2021
Background: Peanut (Arachis hypogaea) allergen powder-dnfp (PTAH; previously known asAR101) is a daily oral immunotherapy approved to mitigate allergic reactions after accidental peanut exposure in peanut-allergic individuals aged 4-17 years.
Smith, Alex +11 more
core +1 more source

Management of chronic urticaria: Current status and future prospect

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Chronic urticaria is driven by mast cell activation through autoimmune, inflammatory, and neuroimmune pathways. A structured approach combining diagnosis, patient‐reported outcomes, stepwise therapy, treatment optimization, monitoring and emerging targeted agents may improve disease control and enable more personalized management.
Andaç Salman +15 more
wiley +1 more source

Real-life safety of venom immunotherapy in children and adults: latent class analysis from the Adverse Events Registry

Frontiers in Allergy
BackgroundVenom Immunotherapy (VIT) safety remains a key consideration in daily clinical practice. Currently, there is considerable variation in the reported frequency of adverse events (AE) during VIT, and risk factors have not been fully elucidated ...
Julijana Asllani +22 more
doaj +1 more source

Shortened up-dosing with sublingual immunotherapy drops containing tree allergens is well tolerated and elicits dose-dependent clinical effects during the first pollen season

World Allergy Organization Journal, 2019
Background: This study compared a rapid home-based up-dosing schedule for sublingual immunotherapy (SLIT) drops containing tree pollen allergens with two previously established schedules. Furthermore, the clinical effect of the SLIT was investigated with
Ralph Mösges +12 more
doaj +1 more source

Chronic Spontaneous Urticaria and Psychiatric Symptoms: The Blood–Brain Barrier Hypothesis

Experimental Dermatology, Volume 35, Issue 10, October 2026.
ABSTRACT Chronic spontaneous urticaria (CSU) is a mast cell‐driven inflammatory disease frequently accompanied by anxiety, depression, sleep disturbance, fatigue, and impaired quality of life. Pruritus, disturbed sleep, psychosocial burden, and treatment‐related effects are established contributors to this neuropsychiatric and functional burden ...
Gerasimos N. Konstantinou +4 more
wiley +1 more source

6th International Symposium on Molecular Allergology (ISMA)

Clinical and Translational Allergy, 2016
Table of contents ORAL ABSTRACTS Symposium 1: Biochemistry, structure and environment of the allergen: what makes a protein an allergen? O1 Two cell-membrane peptidases carrying galactose-alpha-1,3-galactose are implicated in delayed anaphylactic ...
Christiane Hilger +471 more
doaj +1 more source

humans
3. good health
chronic spontaneous urticaria

chronic urticaria
urticaria
omalizumab

adult
female
middle aged